Onconetix (NASDAQ:ONCO) Posts Earnings Results, Beats Expectations By $44,973.99 EPS

Onconetix (NASDAQ:ONCO – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($76.01) EPS for the quarter, topping analysts’ consensus estimates of ($45,050.00) by $44,973.99, FiscalAI reports. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.02 million. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%.

Onconetix Price Performance

NASDAQ:ONCO traded down $0.30 during trading hours on Monday, reaching $2.91. 62,174 shares of the stock were exchanged, compared to its average volume of 167,959. The stock has a market cap of $1.72 million, a PE ratio of 0.00 and a beta of 2.62. Onconetix has a twelve month low of $2.76 and a twelve month high of $1,610.00. The firm has a 50 day moving average of $6.24 and a 200 day moving average of $110.32.

Analyst Ratings Changes

A number of equities analysts have issued reports on ONCO shares. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. Wall Street Zen upgraded Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Onconetix currently has an average rating of “Sell”.

Check Out Our Latest Analysis on Onconetix

About Onconetix

(Get Free Report)

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.

Read More

Earnings History for Onconetix (NASDAQ:ONCO)

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.